Kinea Bio

Kinea Bio is a patient-centered biotechnology company dedicated to accelerating the development of next-generation AAV-based gene therapies for the treatment of neuromuscular disorders. With an integrated technology platform designed to address the most critical challenges in the field of gene therapy, Kinea is applying novel targeting and gene regulation technologies, advanced engineered tissue modeling capabilities, and splicing strategies to enable larger and more functional therapeutic cargos than previously possible—all with the goal of creating safer and more effective gene medicines.